Category: News

With great sadness The Alexander Mosley Trust announces the death of Max Mosley, chair of Trustees.  

Researchers at Imperial College have published results of a clinical trial comparing treatment using psilocybin (the active psychedelic element of Magic Mushrooms) with Escitalopram, a leading anti-depressant drug. The study although small (59 patients),  found no significant difference in the efficacy of the two treatments, and no adverse side effects. Given Read more…

Thanks to a donation from the Trust, Alexander Mosley House, a new student accommodation block, will begin construction shortly at St Peter’s College, Oxford, where Alexander was an undergraduate. The college said that the new building will make a transformative difference both to the feel of the College estate and to Read more…

The Trust is supporting the Children’s Radio Foundation, which trains children to create and broadcast radio in South Africa, Zambia, Tanzania, Ivory Coast, Liberia and DRC. Learning the journalistic skills of interviewing, researching, and producing a radio show is empowering for the children, building up confidence and communication skills. It Read more…

Action on Addiction and King’s College London’s Centre for Addiction Science have developed a mobile app to help people in recovery, supported by the Trust. The app helps people recovering from addictions to keep track of their sleeping patterns and also to keep a log of their recovery programme. It Read more…

The new Imperial Centre for Psychedelic Research will build on pioneering work in this area  at Imperial, including a clinical trial funded by the Trust that has made great progress towards developing psilocybin therapy into a licensed treatment for depression. It will also explore the potential for treating other conditions, Read more…

The research programme the Trust has funded at Imperial College to test the efficacy of psilocybin as a treatment for depression has finally received all of the required approvals, and can begin recruiting participants. The trial will compare the results of psilocybin, the active ingredient in Magic Mushrooms, against Escitalopram, Read more…